sponsored
PatientsVille.com Logo

PatientsVille

Interferon Medical Research Studies

Up-to-date List of Interferon Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Interferon Medical Research Studies

Rank Status Study
1 Recruiting Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)
Condition: Hepatitis C Virus Genotype 4 Infection
Interventions: Drug: Asunaprevir;   Drug: Daclatasvir;   Drug: Ribavirin;   Drug: Pegylated Interferon alpha-2a
Outcome Measures: SVR12 Rate;   Number of patients with adverse events;   Treatment discontinuations;   Self-reported symptoms;   Patients' adherence;   SVR 24 rate;   HCV viral load;   Number of patients with virological failure under treatment;   HCV subtypic distribution;   Proportion of patients with resistance mutations to Asunaprevir and/or Daclatasvir in case of virological failure;   Cirrhosis evaluation;   Insulin resistance : HOMA-IR score;   Metabolic syndrome parameters;   Liver fibrosis;   Polymorphism of the gene of IL28B
2 Unknown  Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon
Conditions: Adjuvant;   Stage III Malignant Melanoma;   Interferon Alpha;   Therapy
Intervention: Drug: Interferon-alpha-2b
Outcome Measures: distant metastasis free survival/(DMFI );   overall survival;   time to progression;   toxicity
3 Recruiting Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)
Conditions: Hepatitis C, Chronic;   Liver Diseases;   Interferon Deficiency
Intervention: Drug: Interferon alpha 2b
Outcome Measures: Absolute Blood HCV RNA Copies at designed time points;   IL-28B polymorphism;   HCV genotype;   Alanine Aminotransferase (ALT) and Aspartate transaminase (AST);   Fibrosis stage;   Regular blood test;   Electrocardiography;   Alcohol ,smoking condition;   Drug abuse history
4 Recruiting The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With HCC
Condition: Hepatocellular Carcinoma
Intervention: Drug: Interferon-alpha (IFN-alpha)
Outcome Measures: disease free survival;   overall survival;   time to recurrence;   Number of Participants with Adverse Events
5 Recruiting In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia
Condition: Hepatitis C
Interventions: Drug: Pegylated Interferon alpha;   Drug: Ribavirin
Outcome Measures: Hepcidin levels;   iron metabolism markers;   heamolysis markers;   inosine triphosphatase genetic variants;   erythropoiesis markers
6 Unknown  Pegylated Interferon and Entecavir Combination in Chronic Hepatitis B (CHB)
Condition: Chronic Hepatitis B
Intervention: Drug: Pegalyted Interferon, Entecavir
Outcome Measure: Combination of half dose and reduced duration pegalyted Interferon in combination with entecavir achieves biochemical and virologic response in chronic hepatitis B
7 Unknown  Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C
Conditions: Self Efficacy;   Hepatitis C
Intervention: Drug: pegylated Interferon alpha 2a YPEG-IFN α-2a 180mcg
Outcome Measures: viral clearance at 72 weeks;   Interferon level
8 Recruiting Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
Condition: HIV Infection
Intervention: Drug: Interferon Alpha 2b
Outcome Measures: We will compare viral RNA levels in blood drawn before, during, and after intensification with Interferon.;   HIV-1 genetic sequencing will be performed to determine whether Interferon therapy results in differences in population structure during the 4-week intensification period.
9 Recruiting Random P2 Study of Postoperative Interferon/Fluorouracil vs Low-dose Cisplatin/Fluorouracil for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus.
Condition: Hepatocellular Carcinoma
Interventions: Drug: Interferon Alfa、Fluorouracil;   Drug: Cisplatin、Fluorouracil
Outcome Measures: Two-year overall survival rate;   Progression free survival time;   Overall survival time;   toxicity
10 Unknown  Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B
Condition: Hepatitis B, Chronic
Interventions: Drug: Interferon α plus nucleoside analogue;   Drug: Interferon α
Outcome Measures: HBeAg seroconversion rate;   HBV DNA loss rate;   HBsAg loss rate
11 Not yet recruiting Randomized Phase III of PRRT Versus Interferon
Condition: Gastro-intestinal Neuroendocrine Tumors
Interventions: Drug: Interferon alpha-2b;   Drug: 177Lu-octreotate
Outcome Measures: Progression Free Survival;   Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 response;   Adverse events according to Common Terminology Criteria for Adverse Events version 4.03;   tumor 68Ga-octreotate PET/CT and 18FDG PET/CT uptake at baseline, at mid and end of PRRT treatment
12 Recruiting Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Conditions: High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS;   Drug: Hydroxyurea;   Drug: Aspirin
Outcome Measures: To compare hematologic response rates in patients randomized to treatment with Pegylated Interferon Alfa-2a vs Hydroxyurea in two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET).;   To compare the toxicity, safety and tolerability of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) in the study populations by recording the adverse events that occur during the study using the CTC 4.0 as the guide.;   To compare the hematologic partial response rates on therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea).;   To compare specific pre-defined toxicity and tolerance of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) and validate the utility of sequential structured symptom assessment package of patient reported outcome instruments.;   To compare the impact of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) on key biomarkers of the disease(s) by measuring the JAK2 allele burden.;   To compare the impact of therapy on JAK2-V617F (JAK2), hematopoietic cell clonality in platelets and granulocytes in females, bone marrow histopathology, and cytogenetic abnormalities.;   To estimate survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea).;   To estimate incidence of major cardiovascular events after therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea).
13 Recruiting Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma
Conditions: Adult Liposarcoma;   Adult Synovial Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage IA Adult Soft Tissue Sarcoma;   Stage IB Adult Soft Tissue Sarcoma;   Stage IIA Adult Soft Tissue Sarcoma;   Stage IIB Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Biological: recombinant Interferon gamma;   Other: laboratory biomarker analysis
Outcome Measure: Change in class I MHC expression after treatment with IFN gamma as determined by immunohistochemistry (IHC)
14 Not yet recruiting HBsAg Decline After Pegylated-Interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance
Condition: Chronic Hepatitis B
Interventions: Drug: PEG-Interferon-Alfa-2A;   Drug: Nucleosides
Outcome Measures: Change in log10 HBsAg titer during antiviral therapy;   HBV DNA undetectability and below 400 IU/mL during antiviral therapy and follow-up;   HBeAg seroconversion and loss during antiviral therapy and at end of treatment and 1 and 2 years following end of treatment;   HBsAg loss and HBsAg seroconversion at end of treatment and 1 and 2 years following end of treatment;   Change in log10 HBsAg titer during follow-up;   Mean change in log10 HBsAg titre over time, as estimated from the area between the baseline value and the curve of log10 HBsAg titre divided by the duration of treatment
15 Unknown  MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: bevacizumab;   Biological: recombinant Interferon alpha-2a
Outcome Measures: Dynamic contrast-enhanced MRI defined changes in K-trans after 6 weeks of bevacizumab monotherapy or bevacizumab and low- or standard-dose recombinant Interferon alpha-2a;   Change in vascular permeability (K-trans) and tumor hypoxia at 2 and 6 weeks post-commencement of treatment;   Best overall response;   Progression-free survival;   Time to progression;   Treatment duration of bevacizumab and recombinant Interferon alpha-2a;   Treatment withdrawal;   Dose modification;   Incidence of adverse events;   Number of circulating endothelial cells, circulating endothelial progenitors, and proangiogenic monocytic cells;   Angiogenic factors (e.g., VEGF) and hypoxia-regulated markers;   Correlation of DCE-MRI defined changes in K-trans with clinical response;   Correlation of DCE-MRI defined changes in K-trans with surrogate biomarkers;   Analysis of diffusion MRI and blood oxygen-level dependent MRI changes and comparison with other pharmacodynamic markers
16 Unknown  Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma
Condition: Advanced Renal Cell Carcinoma
Intervention: Drug: Pazopanib + Interferon alpha 2A
Outcome Measures: Maximum tolerated dose (MTD) - Phase I;   Efficacy, response rate (Phase II);   Progression free survival;   Overall Survival;   Toxicity;   Translational Substudy
17 Recruiting A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-Interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-Interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)
Condition: HBeAg(+) Chronic Hepatitis B
Interventions: Drug: Clevudine;   Drug: Clevudine + Peg-Interferon
Outcome Measures: antiviral activity;Proportion of patients with HBV DNA below LOD(HBV DAN levels < 300 copies/mL) by real time PCR;   antiviral activity: The change of HBV DNA from the baseline;   ALT normalization rate;   Proportion sustained complete response of patients with complete response;   Immunological endpoints;   Proportion of patients with HBeAg loss/ HBeAg seroconversion
18 Recruiting Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: IL-2;   Drug: Interferon Alpha-2b
Outcome Measures: Maximum Tolerated Dose (MTD);   Progression-Free Survival (PFS)
19 Recruiting Tasigna and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
Condition: Chronic Myeloid Leukemia
Interventions: Drug: PegInterferon α2b;   Drug: Nilotinib
Outcome Measures: MMR rate at 18 months of nilotinib monotherapy versus nilotinib+pegylated Interferon alpha;   rate of continuous MMR after discontinuation of nilotinib versus pegylated Interferon alpha;   rate of CCyR and MMR;   Time to CCyR, MMR, MR4 and MR4.5;   rate of MR4 and MR4.5 during maintenance therapy and after discontinuation;   Progression-Free Survival (PFS);   Rate of patients off treatment for at least 6 months;   safety and tolerability profile of nilotinib in comparison with nilotinib+pegylated Interferon alpha and pegylated Interferon alpha;   patients compliance to nilotinib based therapies;   quality of life during induction therapy with ilotinib versus nilotinib+pegylated Interferon alpha and during maintenance therapy with nilotinib versus pegylated Interferon alpha;   pharmacoeconomics of the treatment strategies;   Overall Survival (OS)
20 Recruiting The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis
Conditions: Sepsis;   Septic Shock
Interventions: Drug: Interferon-gamma, Recombinant;   Other: Saline 0.9%
Outcome Measures: The primary endpoint is the tumor necrosis factor (TNF)-α secretion by ex vivo lipopolysaccharide (LPS)-stimulated leukocytes as a marker of immunosufficiency/antimicrobial response.;   Outcome of bacterial infection (occurrence of secondary and/or opportunistic infections, duration of antibacterial treatment, microbiological evaluation);   Hemodynamic stability (noradrenalin infusion rate, amount of infused fluids per day, amount of urine produced per day, daily fluid balance);   Mortality (including time to death) at week 2 and week 6 after end of treatment (all causes);   Length of stay at ICU and duration of hospitalization;   Organ function;   Production of other cytokines by leukocytes ex vivo stimulated with various stimuli (including LPS, peptidoglycan, candida);   Markers of "immune status" (including human leukocyte antigen expression on monocytes (mHLA)-DR and programmed death (PD)-1 expression, interleukin (IL)-6 plasma concentration);   the correlation between the level of immunoparalysis (indicated by the commonly used marker mHLA-DR and new markers of "immune status" found), and effectiveness of IFN-γ (indicated by TNF-α secretion by ex vivo LPS-stimulated PBMC's).;   Transcriptional activity of leukocytes, including microarrays with a focus on inflammatory pathways;   Changes in phenotype or gene expression caused by mechanisms other than changes in the underlying DNA sequence (epigenetic modifications);   reversibility of monocytes tolerance

These studies may lead to new treatments and are adding insight into Interferon etiology and treatment.

A major focus of Interferon research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Interferon